

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Golden Meditech Holdings Limited
金衛醫療集團有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 00801)

**RE-DESIGNATION OF DIRECTORS
AND CHANGES OF MEMBERS OF BOARD COMMITTEES**

The Board of the Company announces that with effect from 26 April 2018:

1. Mr. Feng Wen has been re-designated from an independent non-executive Director to an executive Director;
2. Mr. Gao Yue has been re-designated from a non-executive Director to an independent non-executive Director;
3. Mr. Feng Wen has ceased to act as a member and the chairman of the Remuneration Committee and the Nomination Committee and a member of the Audit Committee; and
4. Mr. Gao Yue has been appointed as a member and the chairman of the Remuneration Committee and the Nomination Committee and a member of the Audit Committee in replacement of Mr. Feng Wen.

INTRODUCTION

The board (the “**Board**”) of directors (the “**Directors**”) of Golden Meditech Holdings Limited (the “**Company**” and, together with its subsidiaries, the “**Group**”) announces the re-designation of Directors and changes of members of Board committees as described below, both of which came into effect from 26 April 2018.

RE-DESIGNATION OF DIRECTORS AND CHANGES OF MEMBERS OF BOARD COMMITTEES

Mr. Feng Wen, an independent non-executive Director, has been re-designated as an executive Director and ceased to act as a member and the chairman of the remuneration committee (the “**Remuneration Committee**”) and the nomination committee (the “**Nomination Committee**”) and a member of the audit committee (the “**Audit Committee**”) of the Company with effect from 26 April 2018.

Mr. Gao Yue, a non-executive Director, has been re-designated as an independent non-executive Director and has been appointed as a member and the chairman of the Remuneration Committee and the Nomination Committee and a member of the Audit Committee with effect from 26 April 2018.

Details (including biography) of Mr. Feng Wen

Mr. Feng Wen, aged 50, was appointed as an independent non-executive Director, a member and the chairman of the Remuneration Committee and the Nomination Committee and a member of Audit Committee on 25 September 2012. Mr. Feng Wen is currently the chairman of the board of Zhong He Hou De Investment Management Co., Ltd* (中和厚德投資管理有限公司), an independent director of Beijing Boer Communication Technology Co., Ltd (北京波爾通信技術股份有限公司) and Beijing ConST Instruments Technology, Inc. (北京康斯特儀表科技股份有限公司), previously a chief executive officer of National Investments Fund Limited, a company listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the secretary to the board of directors of China Investment Development Co., Ltd. (中投發展有限責任公司). Mr. Feng Wen had worked for the General Office of the Ministry of Health of the People’s Republic of China and a number of military hospitals for over 20 years. Mr. Feng Wen graduated from the Medical Department of the Third Military Medical University in 1992 and obtained a master degree from the School of Public Administration, Renmin University of China (中國人民大學) in 2006.

Save as disclosed herein, Mr. Feng Wen did not hold any directorship in other publicly listed companies in the last three years and does not have any relationship with any Directors, senior management or substantial shareholders or controlling shareholders of the Company. As at the date of this announcement, Mr. Feng Wen did not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Mr. Feng Wen entered into a service contract with the Company commencing on 26 April 2018 and continuing thereafter until terminated by either party giving to the other not less than 90 days’ notice in writing. His appointment is subject to retirement by rotation and re-election at annual general meeting in accordance with the articles

of association of the Company and the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”). Pursuant to Mr. Feng Wen’s service contract, he is entitled to an annual director’s fee of HK\$1,300,000 and an annual discretionary bonus of such amount as determined at the sole discretion of the Board. The emolument of Mr. Feng Wen was determined with reference to his duties and responsibilities, the Company’s performance as well as remuneration benchmark in the industry and the prevailing market conditions.

Save as disclosed herein, there are no other matters concerning the re-designation of Mr. Feng Wen as an executive Director that need to be brought to the attention of the shareholders of the Company, and there is no other information required to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules.

Details (including biography) of Mr. Gao Yue

Mr. Gao Yue, aged 45, was appointed as a non-executive Director on 14 November 2014. He graduated from the Law School of Renmin University of China in 1996 and was admitted to the Chinese bar in 1998. Thereafter, Mr. Gao Yue worked as an attorney-at-law and a partner in Beijing Xinli Law Firm and Beijing Fu Sheng Law Firm respectively. From August 2004 to April 2012, he practised law as a partner in King & Wood PRC Lawyers. From May 2012 to July 2016, Mr. Gao Yue worked as a partner of Commerce and Finance Law Offices. From July 2016 onwards, he has been served as a partner of 北京安生律師事務所 (formerly known as Beijing L&L Law Firm).

Mr. Gao Yue specialises in litigation, arbitration, financing, mergers and acquisitions and real estate.

Mr. Gao Yue provides legal service to both domestic and international investment companies, banks and insurance companies in respect of litigation and arbitration in China and abroad. His disputes resolution experience covers disputes in investment, construction, real estate development, company control and intellectual property rights.

Mr. Gao Yue also advises many real estate companies on matters relating to financing, mergers and acquisitions in China and abroad. Mr. Gao Yue has advised many prestigious international investment banks and domestic asset management companies in acquisition and disposal projects of non-performing loans of offshore and onshore banks. Mr. Gao Yue also has experience in large-scale investment projects, domestically and abroad, including participation in project structure design, due diligence, negotiation, documents drafting, provision of legal analysis and opinion and completion of legal procedures.

Save as disclosed herein, Mr. Gao Yue did not hold any directorship in other publicly listed companies in the last three years.

Mr. Gao Yue has entered into a service contract with the Company for a term of one year commencing from 26 April 2018 provided that at any time during the term of appointment, either party may terminate the appointment by giving to the other not less than 30 days' notice in writing. His appointment is subject to retirement by rotation and re-election at annual general meeting in accordance with the articles of association of the Company and the Listing Rules. Pursuant to Mr. Gao Yue's service contract, he is entitled to an annual remuneration of HK\$60,000 and an annual discretionary bonus of such amount as determined at the sole discretion of the Board. The emolument of Mr. Gao Yue was determined with reference to his duties and responsibilities, the Company's performance as well as remuneration benchmark in the industry and the prevailing market conditions.

Mr. Gao Yue is the son of Mr. Gao Zong Ze, who ceased to act as an independent non-executive Director with effect from 19 September 2014. Save as disclosed herein, Mr. Gao Yue does not have any relationship with other Directors, senior management, substantial shareholders or controlling shareholders of the Company.

As at the date of this announcement, Mr. Gao Yue does not have any interest in the shares of the Company which is required to be disclosed under Part XV of the Securities and Futures Ordinance.

Save as disclosed herein, there are no other matters concerning the re-designation of Mr. Gao Yue as an independent non-executive Director that need to be brought to the attention of the shareholders of the Company, and there is no other information required to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules.

By order of the Board
Golden Meditech Holdings Limited
Kam Yuen
Chairman

Hong Kong, 26 April 2018

As at the date of this announcement, the Board comprises 8 Directors. The executive Directors are Mr. Kam Yuen (Chairman), Mr. Kong Kam Yu and Mr. Feng Wen; the non-executive Director is Ms. Zheng Ting; and the independent non-executive Directors are Prof. Cao Gang, Prof. Gu Qiao, Mr. Gao Yue and Mr. Daniel Foa.